pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

被引:0
|
作者
Kobayashi, K
Bouscarel, B
Matsuzaki, Y
Ceryak, S
Kudoh, S
Fromm, H
机构
[1] George Washington Univ, Med Ctr, Div Gastroenterol & Nutr, Washington, DC 20037 USA
[2] Nippon Med Sch, Dept Internal Med 4, Tokyo 113, Japan
[3] George Washington Univ, Dept Biochem & Mol Biol, Washington, DC USA
[4] Univ Tsukuba, Div Gastroenterol, Ibaraki, Osaka, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Irinotecan (CPT-11) and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), are believed to be reabsorbed by intestinal cells and to enter the entero-hepatic circulation, but there is little information to date. Our objective was to investigate the intestinal transport of CPT-11 and SN-38 in correlation with their associated cytotoxicity. Using either isolated hamster intestinal epithelial cells or/and human colon carcinoma HT29 cells, the uptake rates of [C-14]CPT-11 and [C-14]SN-38, both as respective non-ionic lactone form at acidic pH and anionic carboxylate form at basic pH, were investigated by the rapid vacuum filtration technique. The effect of physiologic intestinal luminal pH (6.2-8.0) on the uptake rate and cytotoxicity of SN-38 were estimated by the above method and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, respectively. The lactone forms of CPT-11 and SN-38 were transported passively, while the respective carboxylate form was absorbed actively. Uptake rates of both lactones were significantly higher than those of their carboxylates, Under physiologic pH, the respective uptake rates of CPT-11 and SN-38 were pH sensitive and decreased significantly by around 65%, at pH greater than 6.8. Furthermore, with decreasing pH, a higher uptake rate of SN-38 into HT29 cells correlates with a greater cytotoxic effect (r = 0.987). CPT-11 and SN-38 have absorption characteristics of weakly basic drugs such as short-chain fatty acids, suggesting that alkalization of the intestinal lumen may be critical to reduce their reabsorption and associated side effects. Int. J. Cancer 83:491-496, 1999. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 50 条
  • [31] Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives
    Mullangi, Ramesh
    Ahlawat, Preeti
    Srinivas, Nuggehally R.
    BIOMEDICAL CHROMATOGRAPHY, 2010, 24 (01) : 104 - 123
  • [32] EFFECT OF BEVACIZUMAB ON P-GLYCOPROTEIN ACTIVITY AND ON THE PHARMACOKINETICS OF IRINOTECAN AND ITS MAIN ACTIVE METABOLITE (SN-38) IN VIVO
    Alili, Jean-Meidi
    Noel-Hudson, Marie-Sophie
    Chu, Celine
    Abbara, Chadi
    Farinotti, Robert
    Bonhomme-Faivre, Laurence
    ANNALS OF ONCOLOGY, 2012, 23 : 81 - 81
  • [33] Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice
    Mallick, Pankajini
    Shah, Pranav
    Gandhi, Adarsh
    Ghose, Romi
    LIFE SCIENCES, 2015, 139 : 132 - 138
  • [34] Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells
    Saga, Y
    Mizukami, H
    Suzuki, M
    Kohno, T
    Urabe, M
    Ozawa, K
    Sato, I
    CLINICAL CANCER RESEARCH, 2002, 8 (05) : 1248 - 1252
  • [35] Effects of SN-38, an active metabolite of irinotecan on p53 mediated apoptosis in human hepatocellular carcinoma cells
    Takeba, Yuko
    Kumai, Toshio
    Matsumoto, Naoki
    Kobayashi, Shinichi
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 63 - 63
  • [36] In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
    Kano, Y
    Akutsu, M
    Tsunoda, S
    Mori, K
    Suzuki, K
    Adachi, KI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (02) : 91 - 98
  • [37] In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
    Yasuhiko Kano
    Miyuki Akutsu
    Saburo Tsunoda
    Koyoshi Mori
    Kenichi Suzuki
    Ken-Ichi Adachi
    Cancer Chemotherapy and Pharmacology, 1998, 42 : 91 - 98
  • [38] Preclinical evaluation of CPT-11 and its active metabolite SN-38
    Lavelle, F
    Bissery, MC
    Andre, S
    Roquet, F
    Riou, JF
    SEMINARS IN ONCOLOGY, 1996, 23 (01) : 11 - 20
  • [39] Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans
    Fujita, Ken-ichi
    Sugiura, Tomoko
    Okumura, Hidenori
    Umeda, Saki
    Nakamichi, Noritaka
    Watanabe, Yusuke
    Suzuki, Hiromichi
    Sunakawa, Yu
    Shimada, Ken
    Kawara, Kaori
    Sasaki, Yasutsuna
    Kato, Yukio
    PHARMACEUTICAL RESEARCH, 2014, 31 (01) : 204 - 215
  • [40] Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans
    Ken-ichi Fujita
    Tomoko Sugiura
    Hidenori Okumura
    Saki Umeda
    Noritaka Nakamichi
    Yusuke Watanabe
    Hiromichi Suzuki
    Yu Sunakawa
    Ken Shimada
    Kaori Kawara
    Yasutsuna Sasaki
    Yukio Kato
    Pharmaceutical Research, 2014, 31 : 204 - 215